Confirming Antiphospholipid Syndrome Diagnosis
To confirm APS diagnosis, you must demonstrate persistent antiphospholipid antibodies (at least 12 weeks apart) in a patient with characteristic clinical manifestations—specifically thrombosis (arterial or venous) or pregnancy morbidity (recurrent early losses, late fetal death with preeclampsia/placental insufficiency, or premature birth due to severe preeclampsia). 1
Laboratory Testing Algorithm
Step 1: Order the Three Core Antibody Tests
You must test for all three antibody groups simultaneously 1, 2:
- Lupus anticoagulant (LA) - functional coagulation assay
- Anticardiolipin antibodies (aCL) - IgG and IgM isotypes by ELISA
- Anti-β2-glycoprotein I antibodies (aβ2GPI) - IgG and IgM isotypes by ELISA
Critical timing consideration: Do not test during an acute thrombotic event or within 12 weeks of it, as transient antibodies can cause false positives 2. Similarly, avoid testing during acute infections or immediately postpartum.
Step 2: Interpret Initial Results
For solid-phase assays (aCL and aβ2GPI) 1:
- Moderate titer: ≥40 Units (GPL or MPL)
- High titer: ≥80 Units
- Titers <40 Units are no longer considered clinically significant for APS classification
- The 99th percentile cutoff has been abandoned
For lupus anticoagulant 2:
- Positive LA is the strongest predictor of both thrombosis and adverse pregnancy outcomes
- Major pitfall: Anticoagulation interferes with LA testing. If patient is on warfarin, consider Taipan snake venom time or Ecarin clotting time. If on DOACs, use removal agents or wait for drug clearance 2
Step 3: Confirm Persistence
You must repeat positive tests after at least 12 weeks to confirm persistence 1, 3. This is non-negotiable for diagnosis. Transient antibodies from infections or medications do not constitute APS.
Risk Stratification Based on Antibody Profile
Triple positivity (LA + aCL IgG/IgM + aβ2GPI IgG/IgM all positive) identifies the highest-risk patients 4:
- These patients have the greatest thrombotic risk
- Require most aggressive anticoagulation
- Should never receive direct oral anticoagulants 5
Important caveat about IgM isotypes: While the 2023 ACR/EULAR criteria downgraded isolated IgM antibodies (especially at moderate titers), in clinical practice you should not completely dismiss them—they may still indicate risk in the right clinical context 1. However, isolated IgM <40 Units has minimal clinical significance 6.
Clinical Manifestations That Trigger Testing
Thrombotic Events
- Any unprovoked venous thromboembolism
- Arterial thrombosis (especially in young patients without traditional risk factors)
- Recurrent thrombosis despite anticoagulation
- Thrombosis at unusual sites (cerebral, mesenteric, hepatic veins)
Pregnancy Morbidity 6
- Three or more consecutive spontaneous abortions <10 weeks gestation
- One or more unexplained fetal deaths ≥10 weeks (but note: isolated late fetal death without preeclampsia or placental insufficiency has weak association with APS)
- Premature birth <34 weeks due to severe preeclampsia, eclampsia, or placental insufficiency
The new 2023 criteria emphasize that obstetric APS is primarily driven by preeclampsia and placental insufficiency 6.
Common Diagnostic Pitfalls to Avoid
Do not use classification criteria as diagnostic criteria 1: Classification criteria are designed for research homogeneity and prioritize specificity. In clinical practice, you may diagnose and treat APS in patients who don't meet strict classification criteria if the clinical picture is compelling.
Beware of assay variability 2: Different laboratories use different methods for aCL and aβ2GPI testing, leading to significant inter-assay differences. When possible, use the same laboratory for repeat testing.
Do not test asymptomatic patients 3 except in the context of systemic lupus erythematosus, where screening may be warranted.
Recognize seronegative APS 7: Some patients have classic clinical features but negative standard antibody tests, possibly due to non-criteria antibodies (like anti-phosphatidylserine/prothrombin or anti-domain I β2GPI antibodies) or transient immunosuppression. Consider testing for these additional antibodies in patients with high clinical suspicion but negative standard tests 2.
Additional Testing Considerations
Non-criteria antibodies that may help in specific situations 2:
- Anti-phosphatidylserine/prothrombin antibodies (aPS/PT)
- Anti-domain I β2GPI antibodies
These are useful for risk stratification and may help diagnose patients with incomplete antibody profiles, but are not required for standard diagnosis 2.
The integrated approach: Request an interpretative comment from your laboratory on the report, as laboratory-clinician collaboration is mandatory for accurate APS diagnosis 2.